Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19

• Status: Completed
• Trial end date: 2020-02-25
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of COVID-19 pneumonia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Public Health Clinical Center
• Treatments: Hydroxychloroquine

Criteria

Inclusion Criteria:

• The participants were diagnosed as COVID-19 pneumonia, according to the notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 4 or update version) made by National Health Commission of the People's Republic of China;

• Participants aged over 18;

• Written the informed consent.

Exclusion Criteria:

• Hypersensitivity to chloroquine or hydroxychloroquine;

• Women during pregnancy;

• Severe heart, lung, kidney, brain, blood diseases or other important systemic diseases;

• Participants with retinal disease, hearing loss;

• Participants with severe neurological and mental illness;

• Subjects were considered to be unable to complete the study, or not suitable for the study by researchers.

Exit criteria:

• Subjects asked to withdraw the study

• Subject will benefit if withdraw according to researchers' suggestions